Mamta Swaroop, MD, FACS, FICS

Director

Dr. Swaroop is an Associate Professor of Surgery in the Division of Trauma and Critical Care Surgery and is a former faculty of the Center for Global Health in the Institute for Public Health and Medicine at Northwestern University’s Feinberg School of Medicine.

Dr. Swaroop has served or serves on multiple national and international leadership boards, including the Association for Academic Surgery (AAS) the Indo-US Academic Council for Emergency and Trauma (ACET), the Global Alliance for Surgical, Obstetric, Trauma and Anaesthesia Care (G4 Alliance), the American Association for the Surgery of Trauma (AAST), and the WHO Global Initiative for Emergency and Essential Surgery (GIEESC). She is Founder and former Executive Director of the Northwestern Trauma and Surgical Initiative, her Global Surgery Lab. She runs an international team in projects ranging from helmet usage to the development of a trauma system for the department of Santa Cruz, Bolivia.

She is the President and Founder of the Sadanah Foundation, a not for profit entity that aims to build sustainable access to healthcare and education in low resource settings.

She completed her General Surgery residency at the University of South Florida in 2009 and her Surgical Critical Care Fellowship at Northwestern in 2010. Dr. Swaroop’s research focus is Academic Global Surgery, including trauma education and prevention. She has worked or is working in Bolivia, India, Cambodia, Bangladesh, and Pakistan. She has authored 30+ peer reviewed research articles, and presented nationally/internationally on Trauma and Global Surgery topics.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org